Molecular and Cellular Mechanisms of the In-stent-thrombosis
|Patients With SAT or LT After Stent Implantation (PCI)|
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Molecular and Cellular Mechanisms of the In-stent-thrombosis. Is it Possible to Predict a In-stent-thrombosis Using Biomarkers?|
- The aim of this study is to establish diagnostic markers for prediction of SAT and LT, respectively, by identification of CD39 and CD73-activity and EPC-number and function, respectively. [ Time Frame: may 08 to may 2010 ]
Biospecimen Retention: Samples Without DNA
1 sample of approximately 30 mL blood will be taken from each patient of both study group.
CD39 and CD73 activity as well as EPC-number and function will be analyzed.
|Study Start Date:||May 2008|
|Study Completion Date:||May 2010|
|Primary Completion Date:||May 2010 (Final data collection date for primary outcome measure)|
Patients having developed an in-stent-thrombosis (40 SAT, 40 LT)
Patients having not developed an in-stent-thrombosis after stent implantation using PTCA
In this prospective, open, not-randomized, controlled single-center pilot study 80 patients having had an in-stent-thrombosis (40 sub-acute thromboses (SAT), 40 late thromboses (LT)) and a control group of 80 patients having not developed a thrombosis will be compared.
The aim of this study is the establishment of diagnostic markers vor prediction of SAT (detection of CD39- and CD73-activity, respectively)and of LT (EPC-number and function, respectively) correspondingly aiming at the early identification of patients with high risk for developing an in-stent-thrombosis.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00652015
|RWTH University Hospital|
|Aachen, Germany, 52057|
|Principal Investigator:||Burcin Özüyaman, MD||RWTH Aachen University|